EGTX Share Price Performance
SEK 5.21
0.88 (20.32%)
Price SEK 5.21
Share PriceSEK 5.21
Egetis Therapeutics AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
EGTX Community Narratives
There are no narratives available yet.
Recent EGTX News & Updates
Egetis Therapeutics AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 07, 2025
- Earnings per share (EPS)
- -0.94
- Gross Margin
- 39.96%
- Net Profit Margin
- -712.90%
- Debt/Equity Ratio
- 25.3%
Egetis Therapeutics AB (publ) Competitors
Snowflake Analysis
About EGTX
- Founded
- 2006
- Employees
- 40
- CEO
- WebsiteView website
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Swedish Market Performance
- 7 Days: 2.5%
- 3 Months: 3.2%
- 1 Year: -1.0%
- Year to Date: 3.1%
The market has climbed 2.7% in the last 7 days, lead by the Industrials sector with a gain of 3.2%. In the last 12 months, the market has been flat. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›